EUVIMEDEUVIMED entdecken
Editorial

Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer

Sakti Chakrabarti iD, Amit Mahipal iD

Pharmacogenomics · 2023

DOI: 10.2217/pgs-2022-0170 ↗

Kurz gefasst

Editorial in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Sakti Chakrabarti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colorectal Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColorectal NeoplasmsHumansNeoplasm, ResidualNeoplasm Recurrence, LocalBiomarkers, Tumor

Stichwörter der Autor:innen

adjuvantcolorectal cancerctDNAminimal residual disease

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

ORCID-Profile: Sakti Chakrabarti, Amit Mahipal

Zitieren

APA

Chakrabarti, S., & Mahipal, A. (2023). Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer. Pharmacogenomics. https://doi.org/10.2217/pgs-2022-0170

Vancouver

Chakrabarti S, Mahipal A. Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer. Pharmacogenomics. 2023. doi:10.2217/pgs-2022-0170

BibTeX
@article{Chakrabarti2023,
  author = {Chakrabarti, Sakti and Mahipal, Amit},
  title = {Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer},
  journal = {Pharmacogenomics},
  year = {2023},
  doi = {10.2217/pgs-2022-0170}
}
Kostenlos starten →